Skin Disorders :: Conditions and Diseases
Dermatology
Pharma Industry / Biotech Industry News From Medical News TodayWHO, Wyeth Launch Trial In Africa To Test New River Blindness Drug Fri, 03 Jul 2009 03:00:00 -0700
The WHO on Wednesday announced plans for a clinical trial to test a new drug that "could halve the treatment period for river blindness [or onchocerciasis], a disease that threatens 100 million people mostly in Africa," AFP/Dow Jones Newswires/CNN Money reports (7/1).
FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter Fri, 03 Jul 2009 02:00:00 -0700
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq(R) is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
Spanish Government Selects Novavax's VLP Technology For Comprehensive Flu Vaccine Solution In Spain Fri, 03 Jul 2009 02:00:00 -0700
Novavax, Inc. (Nasdaq: NVAX) announced its initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of Spain.
Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value Fri, 03 Jul 2009 02:00:00 -0700
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer's disease. As progress in those programs has been made, Eisai announces the status as follows: 1.
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer Chemotherapy In Animal Models Fri, 03 Jul 2009 01:00:00 -0700
Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte.
Acura And King Receive FDA Complete Response Letter Regarding Acurox(R) Fri, 03 Jul 2009 01:00:00 -0700
Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) Tablets CII, an immediate release product intended for the relief of moderate-to-severe pain. The Complete Response Letter raises issues regarding the potential abuse deterrent benefits of Acurox(R).
The Seattle Times: BiotechNews on biotechnology pharmaceutical from BioPortfolio.comLixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer ChemotherapMediLexicon:
KAI Pharmaceuticals Buys Patents from ProgenIndividual.com:
KAI Pharmaceuticals Buys Patents from ProgenTradingMarkets:
The Economist: BiotechnologyMonitor: Third time lucky Thu, 04 Jun 2009 11:53:53 -0000
Industrial biotech: A “third wave” of biotechnology is arriving. Will it be able to avoid a poor reception from the general public this time around?FOR a long time the public has perceived biotechnology to mean dangerous meddling with the genes in food crops. But biotechnology is of course about much more than transgenic food: it also encompasses the use of microbes to make pharmaceuticals, for example. The many benefits of the first wave of biotech products, in medicine, have unfortunately been overshadowed by the supposed risks of biotech’s second wave, in agriculture. Might its third wave—so-called industrial biotech, also known as “white biotech” or “green chemistry”—resolve biotech’s image problem?As with other forms of biotechnology, industrial biotech involves engineering biological molecules and microbes with desirable new properties. What is different is how they are then used: to replace chemical processes with biological ones. Whether this is to produce chemicals for other processes or to create products such as biopolymers with new properties, there is huge scope to harness biology to accomplish what previously needed big, dirty chemical factories, but in cleaner and greener ways. ...
Civil engineering: Filling in the cracks Thu, 30 Apr 2009 11:37:50 -0000
How to preserve concrete with bacteriaCONCRETE is one of the most commonly used building materials. It is cheap, strong and easy to work with. But, as a short walk through any city centre will prove, it cracks easily. The cracking of concrete pavements is merely a nuisance, but cracks in roads, bridges and buildings are a hazard. A way of making concrete that healed such cracks spontaneously would thus be very welcome. And a team led by Henk Jonkers at the Delft University of Technology in the Netherlands may have come up with one.The way to stop concrete cracking is to bung up small cracks before they enlarge. That process of enlargement is caused by water getting into a crack, then freezing in cold weather and thus expanding. This freeze-thaw cycle, a common form of erosion of natural rocks, too, weakens a structure directly and also exposes steel reinforcing rods to water, causing them to rust. ...
North Carolina: Pipettes at the ready Thu, 16 Apr 2009 11:57:43 -0000
The state helps engineer a biotech boomDURING a laboratory session at North Carolina State University in Raleigh, a dozen students gathered around a chromatography column. They were sending clarified lysate through an anion exchange, and some compared notes on the peculiar chemical smell of the classroom. “It’s like bad chicken noodle soup,” said one, wrinkling her nose. Others explained how they had ended up in the protective goggles and booties. Wrennie Edwards said that she had started her career in textiles, but now she was “transitioning” to a livelier field. Megan Crum explained that, growing up in Greensboro, she always wanted to be a vet. But once she got to university she realised that everyone wanted to be one. There were, she thought, more opportunities in biomanufacturing. Her father, who used to work in tobacco, was enthusiastic. ...
Subscribe to Biotechnology_and_Pharmaceuticals RSS feed 
BioSpecifics Technologies Corp. - Produces and licenses collagenase, used as a topical treatment of dermal ulcers such as bedsores and burns. Includes explanation of therapy, investor data and profile of company based in Lynbrook, New York. (Nasdaq: BSTC)
Meta Description: [ Description: BioSpecifics Technologies Corp. is a pharmaceutical company with a major focus on wound healing, and tissue remodeling. It has pioneered the application of collagenase for several disease conditions, notably dermal ulcers, pressure sores (bedsores), and second and third degree burns,... ]
Cambridge Bioclinical Ltd. - Develops therapies for hair loss, psoriasis, acne, eczema and other dermatological disorders. Includes company background, careers and contact details. Based in Harston, Cambridgeshire, UK.
404
Cellegy Pharmaceuticals, Inc. - Develops cosmetic drugs for topical application in dermal diseases, local and systemic medical conditions, including HRT. Lists products by prescription and in clinical trials, with profile of company in South San Francisco, California. (Nasdaq: CLGY)
Connetics Corp. - Principally engaged in rapid commercialization of new therapies in the areas of rheumatology and dermatology. Includes product pipeline, investor relations, recruitment and contacts in Palo Alto, California.
Meta Description: [ Stiefel Laboratories is a unique skin care pharmaceutical company - dermatology is our entire focus, and has been for over 150 years. ]
FibroGen, Inc. - Developing recombinant collagen and gelatin for medical devices and pharmaceutical uses, as well as other therapeutics for scarring, fibrosis, wound healing, regeneration, and tissue engineering.
Galderma SA. - Offers prescription medications for topical treatment of acne, rosacea, melasma, psoriasis, seborrheic dermatitis and fungal infections. Includes overview of dermatology products, global presence and careers. Headquarters in France.
Institut Européen de Biologie Cellulaire (IEB) - Research, development and manufacturing of biomimetic peptides, specializing in dermo-cosmetics for skin regeneration and protection. Based near Toulouse, France. [English and French]
Meta Description: [ L'Institut Européen de Biologie Cellulaire, expert en biotechnologie est le spécialiste des solutions de traitement du vieillissement de la peau. Présentation - Historique - Gamme - Solutions ]
MacroChem Corporation - Researches, develops and commercializes systems which rely on company's patented topical drug delivery technology. Product information and investor data from Lexington, Massachusetts. (Nasdaq: MCHM)
Renovo plc - Developing formulations to prevent and reduce scarring in the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments. Includes product pipeline, clinical research and profile of company in Manchester, England.
Meta Description: [ Renovo - Scar prevention and reduction. About Renovo, the world's leading developer of anti-scarring and scar prevention treatments. ]
Stiefel Laboratories, Inc - Develops, manufactures and markets products for the care and treatment of skin diseases. Includes product descriptions and ingredients, and information on skin disorders. Coral Gables, Florida, USA.
Meta Description: [ Stiefel Laboratories is a unique skin care pharmaceutical company - dermatology is our entire focus, and has been for over 150 years. ]